Back to Search
CHANDRAKALA RAJA, M.D
M.D
Internal Medicine Physician
NPI: 1689635716Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
D45244(MD)
Research & Publications (20)
Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates.
PMID 19188157·Clin Cancer Res·2009
7-preclinical
Growth and spectroscopic characterization of a new organic nonlinear optical crystal: L-alaninium succinate.
PMID 19157964·Spectrochim Acta A Mol Biomol Spectrosc·2009
8-other
Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.
PMID 18347423·Cancer Biol Ther·2008
7-preclinical
Inhibition of HIV-1 by a peptide ligand of the genomic RNA packaging signal Psi.
PMID 18205165·ChemMedChem·2008
8-other
The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy.
PMID 18184988·Phys Med Biol·2008
8-other
Synthesis, growth and characterization of a new nonlinear optical material: 4-phenylpyridinium hydrogen squarate (4PHS).
PMID 17652013·Spectrochim Acta A Mol Biomol Spectrosc·2008
8-other
Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206.
PMID 18708762·Cancer Biol Ther·2008
8-other
Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer.
PMID 17664565·Phys Med Biol·2007
8-other
Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer.
PMID 17582216·Cancer Biol Ther·2007
7-preclinical
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma.
PMID 17495524·Cancer Biol Ther·2007
3-trial
A tryptophan-rich hexapeptide inhibits nucleic acid destabilization chaperoned by the HIV-1 nucleocapsid protein.
PMID 16866372·Biochemistry·2006
4-observational
Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model.
PMID 16575210·Cancer Biol Ther·2006
7-preclinical
Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters.
PMID 15961220·Cancer Lett·2006
8-other
During the early phase of HIV-1 DNA synthesis, nucleocapsid protein directs hybridization of the TAR complementary sequences via the ends of their double-stranded stem.
PMID 16406407·J Mol Biol·2006
8-other
Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.
PMID 16475028·Clin Exp Metastasis·2005
7-preclinical
Intralesional targeted alpha therapy for metastatic melanoma.
PMID 16322682·Cancer Biol Ther·2005
3-trial
In vivo studies of pharmacokinetics and efficacy of Bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27.
PMID 15970703·Cancer Biol Ther·2005
7-preclinical
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate.
PMID 15599383·Br J Cancer·2004
8-other
Hip girth as a predictor of abdominal adiposity in postmenopausal women.
PMID 15325686·Nutrition·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10 N GREENE ST
BALTIMORE, MD 21201 - Phone
- (410) 605-7000
Quick Facts
- NPI
- 1689635716
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile